Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir
Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with Gilead Sciences to produce and distribute HIV drug Lenacapavir in India and 120 LMICs.
Dr. Reddy’s enters into licensing agreement with Gilead Sciences for HIV drug
Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally.
Dr. Reddy’s and Hetero join hands with Gilead to broaden access to HIV drug Lenacapavir in low-income countries
Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.
Dr Reddy’s, Hetero ink royalty-free pact with Gilead
Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture Lenacapavir for HIV treatment in India and 120 LMICs, enhancing access for heavily treatment-experienced adults.
Dr. Reddy’s Secures Licensing Deal with Gilead for Lenacapavir in 120 Countries
The drug is currently approved for treating heavily treatment-experienced (HTE) adults with multi-drug resistant HIV.
Dr. Reddy's inks licensing pact with Gilead to commercialise HIV drug
Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) infection in heavily treatment-experienced adults facing multi-drug resistant HIV-1.
Dr. Reddy’s, Hetero ink deal with Gilead to make, market generic HIV drug lenacapavir
Dr. Reddy's, Hetero, and Mylan partner with Gilead to manufacture generic lenacapavir for HIV prevention in 120 countries.
Dr Reddy's, Hetero sign voluntary licenses with Gilead for HIV drug
Gilead Sciences first launched lenacapavir under the brand name Sunlenca in the United States and European markets in 2022. It is a first-in-class HIV-1 capsid inhibitor
Daily
4h
Dr Reddy's Labs arm Chirotech Technology dissolves
Hyderabad: Dr Reddy's Labs has informed in a BSE filing that Chirotech Technology Limited, UK a step down wholly owned ...
6h
Dr. Reddy's Laboratories Share Price Live Updates: Dr. Reddy's Laboratories shows steady growth
Stay up-to-date with the Dr. Reddy's Laboratories Stock Liveblog, your trusted source for real-time updates and thorough ...
moneycontrol.com
9h
Dr Reddy’s enters pact with Gilead Sciences to manufacture, sell HIV drug Lenacapavir in India and 120 countries
Dr
Reddy
’s Laboratories said it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead ...
2d
on MSN
Dr Reddy's completes acquisition of UK co Haleon's non-US nicotine replacement therapy biz
Hyderabad-based pharma giant Dr Reddy’s Ltd finalizes its largest acquisition by buying British Haleon Plc’s non-US nicotine ...
4h
ITC, Dr Reddy's, Tata Steel, JSW Steel, other stocks in action today
Here is a list of stocks that are set to be in focus during Thursday's session, as participants return to trade after a day's ...
The Week
2d
Dr Nilay Reddy of Hyderabad LV Prasad Eye Hospital dies in Outer Ring Road car accident
Dr. Nilay Reddy, 29, a Cornea and Anterior Segment Fellow at the LV Prasad Eye Hospital, was travelling to the airport from ...
money.rediff
2d
Dr Reddy's Acquires Haleon's NRT Portfolio
Dr Reddy's Laboratories has completed the acquisition of Haleon plc's global Nicotine Replacement Therapy (NRT) portfolio, ...
6d
on MSN
Sell Dr Reddy's, Lupin, Zydus Life, Auro Pharma shares, says UBS, sees up to 20% downside
Global brokerage firm UBS has initiated coverage on as many has half dozen Indian Pharma counters and has suggested to sell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback